KINERET Drug Profile
✉ Email this page to a colleague
Summary for Tradename: KINERET
| High Confidence Patents: | 3 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for KINERET |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KINERET |
Recent Clinical Trials for KINERET
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| CMIC Co, Ltd. Japan | Phase 3 |
| Monash Medical Centre | Phase 1/Phase 2 |
| Monash University | Phase 1/Phase 2 |
Recent Litigation for KINERET
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| AbbVie Inc. v. Hetero USA, Inc. | 2024-08-08 |
| AbbVie Inc. v. Hetero USA, Inc. | 2023-11-20 |
| JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD. | 2023-01-19 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| 2015-06-02 | |
| 2012-09-25 |
Pharmacology for KINERET
| Mechanism of Action | Interleukin 1 Receptor Antagonists |
| Established Pharmacologic Class | Interleukin-1 Receptor Antagonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for KINERET Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for KINERET Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2008-12-24 | Company disclosures |
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2020-07-29 | Company disclosures |
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2022-02-22 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for KINERET Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2033-03-11 | Patent claims search |
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2034-05-23 | Patent claims search |
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2030-05-21 | Patent claims search |
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2032-02-15 | Patent claims search |
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | ⤷ Sign Up | 2035-03-20 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for KINERET
Supplementary Protection Certificates for KINERET
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 10299011 | Germany | ⤷ Sign Up | PRODUCT NAME: KINERET(R) (WIRKSAMER BESTANDTEIL ANAKINRA); REGISTRATION NO/DATE: EU/1/02/203/001-004 20020308 |
| 2002C/023 | Belgium | ⤷ Sign Up | PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001 20020311 |
| C300091 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001-004 20020308 |
| SPC/GB02/026 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ANAKINRA (ALSO KNOWN AS HUMAN IL-1RA); REGISTERED: UK EU/1/02/203/001 20020308; UK EU/1/02/203/002 20020308; UK EU/1/02/203/003 20020308; UK EU/1/02/203/004 20020308 |
| 23/2002 | Austria | ⤷ Sign Up | PRODUCT NAME: ANAKINRA; REGISTRATION NO/DATE: EU/1/02/203/001- EU/1/02/203/004 20020308 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
